Your browser doesn't support javascript.
loading
Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1.
Hioe, Catarina E; Liu, Xiaomei; Banin, Andrew N; Heindel, Daniel W; Klingler, Jéromine; Rao, Priyanka G; Luo, Christina C; Jiang, Xunqing; Pandey, Shilpi; Ordonez, Tracy; Barnette, Philip; Totrov, Maxim; Zhu, Jiang; Nádas, Arthur; Zolla-Pazner, Susan; Upadhyay, Chitra; Shen, Xiaoying; Kong, Xiang-Peng; Hessell, Ann J.
Afiliação
  • Hioe CE; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Liu X; Research Service, James J. Peters VA Medical Center, Bronx, NY, United States.
  • Banin AN; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Heindel DW; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Klingler J; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Rao PG; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Luo CC; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Jiang X; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, United States.
  • Pandey S; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, United States.
  • Ordonez T; Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
  • Barnette P; Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
  • Totrov M; Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
  • Zhu J; Molsoft L.L.C., San Diego, CA, United States.
  • Nádas A; Department of Integrative Structural and Computational Biology and Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States.
  • Zolla-Pazner S; Department of Environment Medicine, New York University Grossman School of Medicine, New York, NY, United States.
  • Upadhyay C; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Shen X; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Kong XP; Division of Surgical Sciences, Department of Surgery, Duke University School of Medicine, Durham, NC, United States.
  • Hessell AJ; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, United States.
Front Immunol ; 14: 1271686, 2023.
Article em En | MEDLINE | ID: mdl-37854587
ABSTRACT

Introduction:

Neutralizing antibodies (Abs) are one of the immune components required to protect against viral infections. However, developing vaccines capable of eliciting neutralizing Abs effective against a broad array of HIV-1 isolates has been an arduous challenge.

Objective:

This study sought to test vaccines aimed to induce Abs against neutralizing epitopes at the V1V2 apex of HIV-1 envelope (Env).

Methods:

Four groups of rabbits received a DNA vaccine expressing the V1V2 domain of the CRF01_AE A244 strain on a trimeric 2J9C scaffold (V1V2-2J9C) along with a protein vaccine consisting of an uncleaved prefusion-optimized A244 Env trimer with V3 truncation (UFO-BG.ΔV3) or a V1V2-2J9C protein and their respective immune complexes (ICs). These IC vaccines were made using 2158, a V1V2-specific monoclonal Ab (mAb), which binds the V2i epitope in the underbelly region of V1V2 while allosterically promoting the binding of broadly neutralizing mAb PG9 to its V2 apex epitope in vitro.

Results:

Rabbit groups immunized with the DNA vaccine and uncomplexed or complexed UFO-BG.ΔV3 proteins (DNA/UFO-UC or IC) displayed similar profiles of Env- and V1V2-binding Abs but differed from the rabbits receiving the DNA vaccine and uncomplexed or complexed V1V2-2J9C proteins (DNA/V1V2-UC or IC), which generated more cross-reactive V1V2 Abs without detectable binding to gp120 or gp140 Env. Notably, the DNA/UFO-UC vaccine elicited neutralizing Abs against some heterologous tier 1 and tier 2 viruses from different clades, albeit at low titers and only in a fraction of animals, whereas the DNA/V1V2-UC or IC vaccines did not. In comparison with the DNA/UFO-UC group, the DNA/UFO-IC group showed a trend of higher neutralization against TH023.6 and a greater potency of V1V2-specific Ab-dependent cellular phagocytosis (ADCP) but failed to neutralize heterologous viruses.

Conclusion:

These data demonstrate the capacity of V1V2-2J9C-encoding DNA vaccine in combination with UFO-BG.ΔV3, but not V1V2-2J9C, protein vaccines, to elicit homologous and heterologous neutralizing activities in rabbits. The elicitation of neutralizing and ADCP activities was modulated by delivery of UFO-BG.ΔV3 complexed with V2i mAb 2158.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV / Vacinas de DNA Limite: Animals Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV / Vacinas de DNA Limite: Animals Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos